Higher values indicate aggressive inorganic growth strategies, while lower values suggest a focus on organic growth or a pause in M&A activity.
The total value of goodwill recognized on the balance sheet resulting from business acquisitions completed during the re...
Standard metric for companies pursuing growth through strategic acquisitions.
other_goodwill_acquired_during_period| Segment | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Diagnostics | $97.63M | $97.63M | $97.63M | $97.63M | — | $138.80M | $107.90M | $146.60M |
| Biopharma Laboratory Services | — | — | — | — | — | $0.00 | $0.00 | $0.00 |
| Covance Drug Development | $0.00 | $0.00 | $0.00 | — | $0.00 | — | — | — |
| LabCorp Diagnostics | $141.70M | — | $207.80M | — | $36.40M | — | — | — |
| Total | — | — | — | — | — | — | — | — |
Covance Drug Development, LabCorp Diagnostics were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.